Aspirin should be stopped at day 0 after PCI: pros and cons
EuroIntervention
.
2023 Apr 3;18(16):e1304-e1306.
doi: 10.4244/EIJ-E-23-00001.
Authors
Paul Gurbel
1
,
Udaya Tantry
1
,
Patricia O Guimarães
2
,
Pedro A Lemos
2
3
Affiliations
1
Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA.
2
Hospital Israelita Albert Einstein, São Paulo, Brazil.
3
Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
PMID:
37025087
PMCID:
PMC10068855
DOI:
10.4244/EIJ-E-23-00001
No abstract available
MeSH terms
Aspirin* / adverse effects
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / adverse effects
Substances
Aspirin
Platelet Aggregation Inhibitors